Rua Life Sciences Share Discussion Threads

[harrogate] 30/12/2021 15:50

Some interesting comments- thanks. It is clear that RUA / AOR has been a pretty awful failure over the last 20+ years in so many ways it takes too long to list them. I have been through it all. I had hoped that the new management would break free of that history but I think we now know that they don't have the expertise to get this done and our only hope is a buyout of the lot. I am not as optimistic on that as some as while some progress has been made in some areas this company didn't attract any interest when up for sake 8 or so years ago and could have been snapped up for almost nothing 4 years ago. Will Simone pay £40m now. Let's hope so

[langland] 30/12/2021 14:46

As a non medtech person I find it difficult to fault your arguments.

[aykon] 30/12/2021 13:49

With aortic devices approval is based on 3 things mainly: functionality (this is not at all an issue with a tube graft but more proof need for aortic valve), biocompatibility (Elasteon is proven to be biocompatible through its numerous other clinical uses), and durability ( which is the only angle that FDA could possibly pursue but I can’t see how use of Elasteon as a sealant would lead to weakening of graft structure…and plus you don’t need clinical trial to prove this…this aspect is dealt with by mechanical testing of devices). If I was advising RUA, I would suggest that they involve the right scientific advisors that would provide evidence for what the FDA thinks is lacking for approval!

[aykon] 30/12/2021 13:35

Spurious, I agree with what you are saying. I still don’t see why the FDA would want clinical trial evidence. The only novel use of Elasteon here is as a sealant on graft material. Elasteon is proven to be biocompatible and so there is no question of host implant rejection. Also it’s use as a sealant is unlikely to disrupt underlying graft structure to make it fail as a conduit. That’s why I feel that there is some form of manipulation going on (and some one at the FDA end is likely involved as well). The problem is that all this is difficult to prove/expose and in a business worth billions in the long term…..all this goes on and small players like RUA get taken out long before they become a threat!

[spurious] 30/12/2021 12:55

Hi all
Merry Christmas and hopefully a happier new year
Some thoughts
The delay in gaining FDA approval for our vascular graft is probably not that much of a surprise. The FDA panel will comprise of several influential individuals with previous links to the large Pharma/med device companies in the States. The very companies that would be eyeing our technology which will disrupt their markets and force them to adapt to the new normal.
It would be no surprise for these companies to reach out/influence the key decision makers at FDA to delay approval so they could have more time to ensure a relatively smooth transition to the end of animal product in medical/surgical procedures such as vascular and heart valves and protect their market in the short term.
I agree that the most likely and probably most desirable scenario (from an RUA perspective) will be a sell off of the vascular division and continue to develop Structural heart and Elasteon
However any potential buyer like an Abbot would surely be interested in the Heart Valve as well as the grafts as they are heavily involved in both markets along with Elasteon coated pacer leads and all the potential of developing Elasteon on a global scale.
I therefore think it will be difficult for RUA to pick and choose its future path and feel any global predator will want to swallow it whole. That would guarantee ownership and security of supply with Elasteon and the further benefits of controlling disruptive market moving medical devices in vascular and structural heart.
There has never been a better time for a predator to make a move and as a long term shareholder and supporter the endpoint for shareholder and company should be one and the same... extracting value
I believe there is huge value still to be uncovered.
Regards all
SP

[aimdetective] 29/12/2021 22:46

Because I invest in chunks. Not all at once. I share my research so that those who don't have access to in depth research tools can see what I see. I'm also not arrogant enough to think my research will move the share price enough so I cant buy more at certain levels.Appreciate your assumption though.

[harrogate] 29/12/2021 21:46

So what is the logic ? Of course I know nothing about you as I have not been on Twitter but why would you not quietly build your stake and then announce your findings. I assume you are in it to make money and are not done sort of philanthropist?

[aimdetective] 29/12/2021 21:38

You obviously don't know anything about me or my Twitter feed. I post research and build positions.Never judge a book by its cover.

[harrogate] 29/12/2021 21:34

Let's face it. People who want to build a large position don't post that they are going to build a large position. They post that they have after doing so quietly. What would be the logic. Pump and dump by the sound of it.

[aimdetective] 29/12/2021 21:09

Have posted some of my research here.https://twitter.com/aimdective/status/1476156762499825664?s=21

[aimdetective] 29/12/2021 21:08

Bought at 65p today. Will be building a large position over the next couple of months.

[the_real_mr_big] 29/12/2021 17:03

A bird's bush in the hand is always good - just ask D Trump (#grab'embythep*ssy)

[mikeh30] 29/12/2021 13:27

Agree bones, I'm currently on the sidelines but hoping they clarify things to stabilise it. If they are thinking of selling up some of their IP then say it. Some of the recent market fundraises have been savage. They are fine for now but they want to approach those talks from a position of strength

[bones] 29/12/2021 13:12

Mikeh30, my two penn’orth:

The half year report contained a big change in emphasis to previous releases. Prior to that, the general newsflow almost assumed a 510k approval with “first grafts revenue” guidance maintained at Q1/22. The change is stark and reflects that this turn of events was a “major disappointment”;, as the company declared.

The share price was consequently hammered and that is not a surprise in the circumstances as it now brings longer term funding concerns back into play especially as a lot of spending has taken place on the graft production equipment. There is a lot more cautious information in the half year report around this equipment than had been emphasised previously.

It does seem that the company’s third party consultancy advice around the 510k strategy was misplaced enabling a rosey forecast around revenues which left the market well offside. I imagine the consultants have received some stern words from the board.

The emphasis in the half year report now talks in optimistic terms about European approval being important and it would seem that human clinical trials for both Europe and the US will be the next stage. This does however cause considerable delay in commercialisation so it suggests to me that the company might look to cash in some of its pre-trial IP (grafts or heart valve?) which we are told is valuable for the majors to get a piece of. A bird in the hand or two in the bush? The bird in the hand could become a necessity if a further dilutive cash raise is to be avoided.

The company’s aims are all intact and the potential as ever remains. Timing is once more longer term (Aortech revisited!) hence the share price discount.

As you say Mike, we need the FDA requirements to be formalised and some idea of future funding runway through 2022. Until then, it could be a frustrating period.

[mikeh30] 29/12/2021 12:55

Amati are declaring their reductions

[aykon] 29/12/2021 12:49

Looks like someone is dumping stock….either it is a distressed big holder or may even be an II colluding with a big player to facilitate cheap takeover! This is the most likely explanation. Uncertainty around FDA 510k is not the entire cause of this!

[mikeh30] 29/12/2021 12:45

They need to put out a release with total upfront honesty warts and all. The share price is more likely to recover/stabilise if they lay it all out so investors can stop speculating. Too much uncertainty and if they don't address it they'll be raising at a much lower price unfortunately. Get that release out and get it done

[the_real_mr_big] 29/12/2021 12:08

PS looks like dogsh*te capital are still on our side after buying in at 130, so their unrealised loss is bigger than mine lol.

[the_real_mr_big] 29/12/2021 12:07

As long as I'm not looking at the sp, I'm getting more optimistic.

From a glimpse of the FDA 510k clinical studies presentation:

- 10-15% of 510k applications require clinical studies.
Looks like we're just 1-in-10 cases. Big de-stresser for me, as I thought our problems were more along the lines of inability to use 510k route.

- Size of clinical studies dictated by the ability of bench & animal testing to answer questions. Hopefully, we just need a few extra data points satisfied, but wtfdik.

Sitting on a huge loss here, but I can see this bouncing back up on a slither of good news. Until then I'll keep on holding on to this falling knife until I bleed dry. Bring on the FDA response in January.

£15m mcap with £4m in cash and increasing revenues seems like the time to top up. Be greedy when everyone's planting trees, or whatever it was that Buffy said.

[mikeh30] 29/12/2021 12:00

Uncertainty and sentiment trumps everything else on illiquid AIM stocks unfortunately

[the_real_mr_big] 29/12/2021 11:31

Come on. £15m mcap and it's falling. Seriously?

[amt] 23/12/2021 07:57

Buywell asks has Buywell ever spotted an overvalued share Before it has collapsed. Buywell needs to ask Buywell why is investing easy with benefit of hindsight.

[greedy rooster] 22/12/2021 12:05

The latest recruits came at the perfect time.

The CFO has been through this before. The reg and clinical affairs chap arrived 6 weeks too late, but at least we can benefit from his experience.

At current levels an opportunistic approach is an obvious risk. But if they get the new strategy right, with, say a £m strategic investment in new shares from an industry partner, all the angst will dissipate overnight. I did not buy the shares for the grafts or the patches. I bought for the massive heart-valve IP value and the Elasteon enabled disruption as the end of using animal derived material inevitably arrives.

[the_real_mr_big] 22/12/2021 10:09

Amati dumping.
This is bad.

[buywell3] 22/12/2021 07:24

POST REMOVED